Navigation Links
Delcath Highlights Phase III Trial Results Presented at ASCO
Date:6/5/2010

that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs, the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies  and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
2. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
3. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
6. Delcath Systems Granted Third Orphan Drug Designation
7. Delcath Enters Agreement to Sell 869,565 Units
8. Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
9. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
10. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015  Heidrick & Struggles (Nasdaq: HSII ), ... consulting and culture shaping worldwide, today  announced ... lead its global Healthcare and Life Sciences practice. ... Mitchell will lead a team of more than 80 partners, ... and Asia serving clients in ...
(Date:3/30/2015)... 2015  New Jersey Health Foundation, a not-for-profit organization ... of New Jersey , has committed ... announced James M. Golubieski , president. ... program, an additional $500,000 will be available for awards ... research projects that demonstrate exciting potential and may lead ...
(Date:3/30/2015)... March 30, 2015 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a commercial focus on China ... Administration (CFDA) has approved the Company,s application to conduct ... cell carcinoma (OCCC) patients for its proprietary drug candidate ...
(Date:3/30/2015)...    Intrexon Corporation (NYSE: XON ... Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... exclusive strategic collaboration and license agreement to develop ... therapies. This collaboration advances Merck Serono,s comprehensive, science-driven ... immune system,s natural ability to fight tumors. ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4
... All amounts are in U.S. dollars, QUEBEC CITY, Nov. ... AEZ), a global biopharmaceutical company focused on,endocrinology and oncology, today ... 30, 2008., Third Quarter 2008 Highlights, - ... President and CEO of AEterna Zentaris, replacing ...
... in the area of AIDS, geriatric diseases, neurosciences, and drug ... biotechnology reagents is projected to reach $32.5 billion by 2012. ... period is forecast to benefit protein related product markets in ... ...
... Melbourne-based Starfish,Ventures announced today the successful closure ... the largest venture capital fundraising in,Australia. The fund ... The success of this fundraising is an ... ability to foster the development of,innovative companies that, ...
Cached Biology Technology:AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 7AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 8AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results 9World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 2World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 3Starfish Ventures Closes Australia's Largest Venture Capital Fund With $185 Million Tech Fund 2
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
(Date:3/12/2015)... Va. , March 12, 2015 IriTech, ... and a member of the Texas Instruments Design Network, ... Naidu has demonstrated its IriShield USB MK2120U device ... scanning facility for pension distribution. The ... assembled to be marketed in India ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
... the flatworm, planaria, offers new clues for understanding ... Institute have discovered how the worm's cells communicate ... scientists have found that gap-junction (microscopic tunnels directly ... This research, led by Dr. Michael Levin, underlies ...
... new computerized system to easilymonitor the levels of glucose ... study published today in the open access journal BMC ... that assists in the monitoring of glucose levels incritically ... moreefficient than the paper-based method currently used in manyintensive ...
... control what you eat and when, your nervous system ... contain information about energy level, food preferences, and metabolic ... of available food, determined by its smell and taste. ... path of olfactory signals beginning with chemical receptors in ...
Cached Biology News:New understanding of regeneration gained by Forsyth scientists 2How Fruitflies Know It's Time for Lunch 2How Fruitflies Know It's Time for Lunch 3
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: filling ...
... system automates the denaturation and hybridization steps ... convenience for clinical and research personnel. The ... of sample types, is easy to use, ... 50% while ensuring overall precision and accuracy ...
... RNA Sample Buffer is a ... for experimental samples and Perfect ... buffer needs no dilution and ... denaturing gels. Simply mix equal ...
... L1210 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
Biology Products: